HOME » PRODUCTS » COVID-IDR » Pro00105316

Pro00105316
Duke Shared Data and Specimen Repository Regarding COVID Patients

Principal Investigator: Chris Woods

Contact: chris.woods@duke.edu, susanna.naggie@duke.edu

This shared data and biorepository project houses core data and informed consent forms (ICFs) for all Duke University study participants with suspected or confirmed COVID-19 who have consented to sharing data and biospecimen samples for research purposes. Samples may be either collected specifically according to research protocol or include clinical samples left over from COVID testing and treatment of patients at Duke.

This repository provides secure, centralized storage for collecting core data variables of interest and retaining relevant patient samples from COVID-19 research protocols active at Duke. Core data variables were selected in part to match those agreed upon by U.S. academic medical centers, with the intention of increasing the efficiency and effectiveness of de-identified data reuse for population-level research. This shared resource for demographic and longitudinal variables will reduce burdens on research participants, as many questions will now only need to be asked once, rather than each time a given participant joins an additional COVID-19-related study at Duke.

PLEASE NOTE: the data presented below represent a snapshot in time of data and specimens available through this protocol. Data in this repository are continuously updated and counts may change on a daily basis. Each study that participates in this Data and Specimen Repository will have its own separate IRB-approved protocol.
For additional information or assistance please contact: CovidIDRandSpecimensRequest@duke.edu

Start date: January 1, 2020
Stop date: February 19, 2021
Total Participants: 4,454
Total Specimens: 21,135

By Month: Number of Diagnoses, Number of Admissions, and Average Hospitalization Duration

	Jan20	Feb20	Mar20	Apr20	May20	Jun20	Jul20	Aug20	Sep20	Oct20	Nov20	Dec20	Jan21	Feb21
Date of Diagnosis			36	402	600	1172	1137	695	470	576	217	54	10	8
Date of Admission	68	76	82	205	287	282	347	256	203	281	92	65	45	30
Avg. Duration of Hospitalization (Days)	7	11.3	8.3	10.6	10.1	10.8	8.3	9.1	9	8.1	6.5	7.6	5.5	2.6

Number of Sample Collection Timepoints Per Participant and Level of Care

	Highest Level of Care
Sample Collection Points	Home	Outpatient	ED	Inpatient	ICU	*TOTALS*
1	11	1689	763	370	124	2957
2		125	160	229	58	572
3		21	44	126	50	241
4		1	16	4	3	24
> 4		2	8	303	116	429
*TOTALS*	11	1838	991	1032	351	4223

Table 1

Category	Characteristic	Count	Notes
Sex	Male	2467
Sex	Female	1987
Age	0-19	492
Age	20-29	704
Age	30-39	723
Age	40-49	726
Age	50-59	675
Age	60-69	560
Age	70-79	367
Age	80-89	162
Age	90-100	45
Ethnicity	Hispanic Cuban	11
Ethnicity	Hispanic Mexican	572
Ethnicity	Hispanic or Latino	1
Ethnicity	Hispanic Other	755
Ethnicity	Hispanic Puerto Rican	40
Ethnicity	Not Hispanic/Latino	2824
Ethnicity	Not Reported/Declined	223
Ethnicity	Blank	28
Race	American Indian or Alaskan Native	23
Race	Asian	107
Race	Black or African American	1381
Race	Caucasian/White	1579
Race	Native Hawaiian or Other Pacific Islander	17
Race	2 or more races	407
Race	Other	516
Race	Not Reported/Declined	403
Race	Blank	21
BMI	BMI ≥30 (Obese)	1935	Flowsheet data
BMI	BMI <25 (Lean)	629	Flowsheet data
Diagnosis Code	Diabetes	934
Diagnosis Code	Hypertension	712
Diagnosis Code	COPD	97
Diagnosis Code	HIV	41
Diagnosis Code	Heart/Lung Transplant	2
Diagnosis Code	Kidney Transplant	4
Diagnosis Code	Liver Transplant	3
Diagnosis Code	Bowel Transplant	0
Diagnosis Code	Bone Marrow Transplant (BMT)	0
Diagnosis Code	Pregnancy	99
Diagnosis Code	Acute Pulmonary Embolism (PE)	28
Diagnosis Code	Stroke	70
Diagnosis Code	Myocardial Infarction (MI)	179
Trial Participation	Research Trial Participant	298	Z00.6 diagnosis code
Medications	Remdesivir	495
Medications	Apilimod	0
Medications	Baricitinib	56
Medications	Monoclonal Antibodies	42
Medications	Azithromycin	622
Medications	Doxycycline	453
Medications	Ceftriaxone	620
Medications	Heparin	1314
Medications	Lovenox	1137
Medications	Argatroban	5
Medications	Hydroxychloroquine	50
Medications	Chloroquine	0
Medications	Tocilizumab	1
Medications	Dexamethasone	876
Medications	Prednisone	445
Medications	Hydrocortisone	239
Medications	Solumedrol	3
Medications	Infliximab	6
Medications	Abatacept	1
Medications	Casirivimab/Imdevimab	1
Discharge Disposition	Blank	1492
Discharge Disposition	Expired	173
Discharge Disposition	Skilled Nursing Facility	125
Discharge Disposition	Home or Self Care	2486
Discharge Disposition	Home Health Service	85
Discharge Disposition	Hospice	13
Discharge Disposition	Left Against Medical Advice	26
Discharge Disposition	Other Facility	54
Highest Level of Care	ICU	380
Highest Level of Care	Inpatient	1135
Highest Level of Care	ED	993
Highest Level of Care	Outpatient	1850
Highest Level of Care	Home	11
Specimens by Type	Whole Blood	4247
Specimens by Type	Plasma	5441
Specimens by Type	Serum	805
Specimens by Type	Lavage, Bronchoalveaolar	8
Specimens by Type	Lavage, Nasopharyngeal	22
Specimens by Type	Swab, Nasal	437
Specimens by Type	Swab, Nasopharyngeal	10175
O2 Device	Nasal cannula	1165
O2 Device	Other O2	586
O2 Device	High Flow Oxygen	418
O2 Device	Ventilator	251
O2 Device	BiPAP	129
O2 Device	CPAP	124
O2 Device	Trach	39
Highest FiO2	<20	14
Highest FiO2	20-29	43
Highest FiO2	30-39	37
Highest FiO2	40-49	44
Highest FiO2	50-59	45
Highest FiO2	60-69	74
Highest FiO2	70-79	56
Highest FiO2	80-89	78
Highest FiO2	90-100	136
Home Oxygen Orders	GENERIC SUPPLY ORDER: Home Oxygen	16
Home Oxygen Orders	OXYGEN (SUP5303)	7

Pro00105316